S-1/A: NeOnc Technologies Holdings Eyes Nasdaq Listing with Direct Offering of 2.1 Million Shares

NeOnc Technologies Holdings is set to pursue a direct listing on the Nasdaq Global Market, offering 2,101,313 shares for resale by existing stockholders.

Summary

• NeOnc Technologies Holdings is registering for the resale of up to 2,101,313 shares of common stock by existing stockholders as part of a direct listing on the Nasdaq Global Market.
• The company will not receive any proceeds from the sale of these shares.
• NeOnc has engaged RBW Capital Partners LLC as a financial advisor for the direct listing.
• The company has also engaged RBW Capital Partners LLC as a placement agent for a private placement of common stock at $16.00 per share, aiming to raise approximately $10,000,000.
• The company has agreements with investors to sell 624,999 shares of common stock at $16.00 per share.
• NeOnc is an emerging growth company and a smaller reporting company, which allows for reduced disclosure requirements.
• The company has applied to list its common stock on the Nasdaq Global Market under the symbol NTHI.
• NeOnc expects its common stock to begin trading on Nasdaq on or about , 2025.
• The company has incurred significant losses since its inception, with a net loss of $11,898,464 for the year ended December 31, 2024.
• As of December 31, 2024, the company had an accumulated deficit of $50,608,445.
• The company is developing novel drug delivery methods to treat intracranial malignancies, with lead products NEO100 and NEO212 in clinical development.
• NEO100 is being investigated for recurrent malignant glioma and malignant skull-based meningioma, while NEO212 is being developed for primary and secondary brain tumors.
• The company projects that the readout for its Phase II studies with respect to NEO100 could now be feasibly delivered by the end of 2024, advancing our original timeline by a full year from 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is pursuing a Nasdaq listing and has promising drug candidates, it also faces significant financial challenges and risks associated with drug development and commercialization.

Positives

• NEO100 is currently in Phase II trials.
• Licensed large patent portfolio for NEO100 with currently issued patents expiring between 2030-2038.
• Potential in additional multiple indications in underserved markets with large patient populations.
• NEO212 has completed preclinical testing and has received investigational new drug (IND) approval from the United States Food and Drug Administration (FDA).
• The company projects that the readout for its Phase II studies with respect to NEO100 could now be feasibly delivered by the end of 2024, advancing our original timeline by a full year from 2025.

Negatives

• The company has incurred significant losses since its inception and anticipates that it will incur significant and increasing losses for the foreseeable future and we may never achieve or maintain profitability.
• The report of our independent registered public accounting firm included a going concern explanatory paragraph.

Risks

• The direct listing process differs from an initial public offering underwritten on a firm-commitment basis.
• Our common stock currently has no public market.
• An active trading market may not develop or continue to be liquid and the market price of shares of our common stock may be volatile.
• Future sales of common stock by our Registered Stockholders and other existing stockholders could cause our share price to decline.
• You may be diluted by future issuances of preferred stock or additional common stock in connection with our incentive plans, acquisitions or otherwise; future sales of such shares in the public market, or the expectations that such sales may occur, could lower our stock price.
• Because we have no current plans to pay cash dividends on our common stock, you may not receive any return on investment unless you sell your common stock for a price greater than that which you paid for it.
• We are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.
• Our management and principal stockholders own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.
• Our amended and restated certificate of incorporation, in each case, which will become effective in connection with the effectiveness of the registration statement, of which this prospectus forms a part, will provide for an exclusive forum in the Court of Chancery of the State of Delaware for certain disputes between us and our stockholders, which could limit our stockholders ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Future Outlook

The company expects to continue to incur significant and increasing expenses and operating losses for the foreseeable future as it advances its product candidates through clinical development and seeks regulatory approval.

Industry Context

The company operates in the CNS treatment and brain tumor drug markets, which are expected to grow significantly in the coming years. The company is focused on developing novel drug delivery methods to improve the treatment of intracranial malignancies.

Comparison to Industry Standards

• The global central nervous system (CNS) treatment market is expected to grow at 9.4% CAGR to reach $166.5 billion by 2028, and the global brain tumor drug market is expected to grow at CAGR of 9.0% reach $4.4 billion by 2029, according to Fortune Business Insights.
• Radiation therapy still accounts for 38% of the brain cancer treatment market, while drug treatment remains second mostly due to current inefficiencies of drug delivery, according to Grandview Research.
• The GBM drug market is expected to grow at 12.7% CAGR to $2.3 billion by 2029, according to iHealthcare Analyst, with the market being driven by rising geriatric population, growing incidence cases, and a pipeline of new products.
• GBM accounts for up to 54% of gliomas and 16% of all primary brain cancers, according to research published in the journal, Glioblastoma.

Legal Proceedings

• The company is currently in default under the terms of a settlement agreement with Fox Infused, LLC and there is a risk that Fox Infused could institute default proceedings against us which could result in direct and indirect costs to us in defending and responding to such proceedings and could result in operational disruptions that could harm our reputation, brand and results of operations, any of which may affect our ability to raise additional proceeds from the sale of our securities.
• OEP recently informed the Company that it believes we are currently obligated to pay such amount; while we do not agree with this assertion, there is a risk that OEP could institute additional proceedings against us which could result in direct and indirect costs to us in defending and responding to such proceedings and could result in operational disruptions that could harm our reputation, brand and result of operations, any of which may affect our ability to raise additional proceeds from the sale of our securities.

Related Party Transactions

• The company has engaged in several related party transactions, including loans from HCWG LLC, a company owned in part by executive officers and directors, and payments to USC, where the CEO is a faculty member.
• On June 14, 2024, the Company reached an agreement with HCWG to convert the outstanding principal and interest on the Bridge Loan totaling $11,748,464 to 979,039 shares of common stock at $12 per share.

Stakeholder Impact

• Shareholders may experience dilution from future stock issuances.
• The company's success depends on the acceptance of its products by physicians, patients, and third-party payors.
• Employees' stock options may be affected by movements in the company's stock price.
• The company's ability to attract and retain qualified personnel is critical to its success.

Next Steps

• Complete the direct listing process on the Nasdaq Global Market.
• Continue clinical trials for NEO100 and NEO212.
• Pursue regulatory approvals for product candidates.
• Explore potential collaborations and partnerships.
• Continue research and development activities.

Key Dates